JP2010540547A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540547A5
JP2010540547A5 JP2010527091A JP2010527091A JP2010540547A5 JP 2010540547 A5 JP2010540547 A5 JP 2010540547A5 JP 2010527091 A JP2010527091 A JP 2010527091A JP 2010527091 A JP2010527091 A JP 2010527091A JP 2010540547 A5 JP2010540547 A5 JP 2010540547A5
Authority
JP
Japan
Prior art keywords
aliskiren
combination
important
dissolution
fixed dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010527091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/077416 external-priority patent/WO2009045795A2/en
Publication of JP2010540547A publication Critical patent/JP2010540547A/ja
Publication of JP2010540547A5 publication Critical patent/JP2010540547A5/ja
Withdrawn legal-status Critical Current

Links

JP2010527091A 2007-09-28 2008-09-24 アリスキレンおよびバルサルタンのガレヌス製剤 Withdrawn JP2010540547A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97590907P 2007-09-28 2007-09-28
US97591907P 2007-09-28 2007-09-28
US97590107P 2007-09-28 2007-09-28
US97592507P 2007-09-28 2007-09-28
PCT/US2008/077416 WO2009045795A2 (en) 2007-09-28 2008-09-24 Galenical formulations of aliskiren and valsartan

Publications (2)

Publication Number Publication Date
JP2010540547A JP2010540547A (ja) 2010-12-24
JP2010540547A5 true JP2010540547A5 (enExample) 2012-11-01

Family

ID=40377183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527091A Withdrawn JP2010540547A (ja) 2007-09-28 2008-09-24 アリスキレンおよびバルサルタンのガレヌス製剤

Country Status (18)

Country Link
US (1) US20100209480A1 (enExample)
EP (1) EP2205233A2 (enExample)
JP (1) JP2010540547A (enExample)
KR (1) KR20100063090A (enExample)
CN (1) CN101808631A (enExample)
AR (1) AR066168A1 (enExample)
AU (1) AU2008309058B2 (enExample)
BR (1) BRPI0817442A2 (enExample)
CA (1) CA2698330A1 (enExample)
CL (1) CL2008002829A1 (enExample)
CO (1) CO6270217A2 (enExample)
EC (1) ECSP10010052A (enExample)
MA (1) MA31706B1 (enExample)
MX (1) MX2010003441A (enExample)
PE (1) PE20090654A1 (enExample)
TN (1) TN2010000135A1 (enExample)
TW (1) TW200924737A (enExample)
WO (1) WO2009045795A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091203A1 (es) * 2007-09-28 2009-09-11 Novartis Ag Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
MX2011009844A (es) * 2009-03-20 2011-09-29 Novartis Ag Composicion farmaceutica que comprende alisquireno.
CN102348452A (zh) * 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
AR080683A1 (es) * 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2766423A1 (en) * 2011-10-12 2014-08-20 Dow Global Technologies LLC Injection-molded dosage form
WO2013098268A2 (en) * 2011-12-26 2013-07-04 Novartis Ag Tablets and dry-coated agents
CN103349652B (zh) * 2013-05-11 2014-11-19 辽宁大学 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
EP2248520A3 (en) * 2004-10-08 2010-11-17 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
KR20080000624A (ko) * 2005-04-27 2008-01-02 노파르티스 아게 아테롬성동맥경화증의 치료 방법

Similar Documents

Publication Publication Date Title
MX2022002952A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
JP2014005302A5 (enExample)
WO2009034541A3 (en) Controlled release pharmaceutical dosage forms of trimetazidine
JP2007302683A5 (enExample)
RU2009106681A (ru) Гранулированные фармацевтические композиции
JP2015515459A5 (enExample)
NO20081325L (no) Nye doseringsformuleringer
WO2006015943A3 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2003072025A3 (en) Modified release formulations of at least one form of tramadol
JP2005538121A5 (ja) 多重遅延放出抗ウイルス物質産物、その使用法と製剤
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
JP2009534294A5 (enExample)
EA031255B1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
SI2729130T1 (en) Combined formulations of darunavir
CY1115709T1 (el) Φαρμακευτικη μορφη περιεχουσα φλουπιρτινη με ελεγχομενη αποδεσμευση της δραστικης ουσιας
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
TN2010000135A1 (en) Galenical formulations of organic compounds
JP2020510073A5 (enExample)
RU2015138784A (ru) Фармацевтическая композиция в виде мультичастиц, содержащая множество гранул двух видов
DE602006015062D1 (de) 3-aminocarbazolverbindungen, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung
RU2016106336A (ru) Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения
Alhamhoom et al. Formulation and evaluation of polymeric spherical agglomerates-based porous orodispersible tablets of cilnidipine
JP2016516031A5 (enExample)